Cargando…
Endurance of erythrocyte series in chemotherapy
Hematopoietic bone marrow toxicity is most often the limiting factor for chemotherapy doses. Increasing the intensity of chemotherapy doses (higher doses or more frequent administration) would improve antitumor effects, but the hematological toxicity does not allow these dose increases. This study e...
Autores principales: | Săftescu, Sorin, Popovici, Dorel, Oprean, Cristina, Negru, Alina, Croitoru, Adina, Zemba, Mihail, Yasar, Ionela, Preda, Maria, Negru, Șerban |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604759/ https://www.ncbi.nlm.nih.gov/pubmed/33149778 http://dx.doi.org/10.3892/etm.2020.9344 |
Ejemplares similares
-
Determining factors of renal dysfunction during cisplatin chemotherapy
por: Săftescu, Sorin, et al.
Publicado: (2021) -
Comparative hematological profiles for dose-dense vs. regular anthracycline-based neoadjuvant chemotherapy in non-metastatic breast cancer
por: Popovici, Dorel, et al.
Publicado: (2021) -
Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020) -
Anthropometry in the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020) -
Nutritional Interventions to Improve Cachexia Outcomes in Cancer—A Systematic Review
por: Braha, Adina, et al.
Publicado: (2022)